ROSEN, A LONGSTANDING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities during the specified Class Period, indicating potential legal claims against the company for misleading information regarding its product candidate RGX-111 [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [1][3]. Group 2: Allegations Against REGENXBIO - The lawsuit claims that REGENXBIO provided misleading information about the efficacy and safety of RGX-111, a gene therapy for Hurler syndrome, while presenting overly positive assertions about its trial success [5]. - Defendants allegedly concealed material adverse facts regarding the RGX-111 trial, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].